Overview

Nonalcoholic Steatohepatitis (NASH) Market is forecasted to value over USD 54 billion by 2027 end and register a CAGR of 58.6% from the forecast period 2020-2027.

FutureWise Market Research has illustrated a report on the Nonalcoholic Steatohepatitis (NASH) Market. The report provides an in-depth anatomy of market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.
The Nonalcoholic Steatohepatitis (NASH) Market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Nonalcoholic Steatohepatitis (NASH) Market are:    

• Genfit
• Intercept Pharmaceuticals
• Gilead Sciences
• Tobira Therapeutics
• Galmed Pharmaceuticals
• Bristol-Myers Squibb
• Cirius Therapeutics
• Conatus Pharmaceuticals
• Allergan
• Inventiva
(Note: The list of the major players will be updated with the latest market scenario and trends)

Nonalcoholic Steatohepatitis (NASH) Market Segmentation:

By Disease Cause 

• Hypertension
• Heart Disease
• High Blood Lipid
• Type 2 Diabetes
• Obesity

By Drug Type 

• Vitamin E & Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib
• Cenicriviroc
• Others

By End User 

• Hospitals
• Clinics
• Homecare settings

By Region

• North America
• Europe
• Asia-Pacific
• Rest of the world

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the market by disease cause, by drug type, by end user and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industryspecific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
           1.1. Objectives of the Study 
           1.2. Market Definition 
           1.3. Market Scope 
                   1.3.1. Years Considered for the Study
                   1.3.2. Market Covered
           1.4. Currency 
           1.5. Limitations 
           1.6. Stakeholders 
 2.  Research Methodology 
           2.1. Research Data 
                   2.1.1. Secondary Data
                           2.1.1.1. Key Data from Secondary Sources
                   2.1.2. Primary Data
                            2.1.2.1. Key Data from Primary Sources
           2.2. Market Size Estimation 
           2.3. Market Breakdown and Data Triangulation 
           2.4. Assumptions for the Study  
3. Executive Summary
           3.1. Market Outlook
           3.2. Segment Outlook
           3.3. Competitive Insights
4. Global Nonalcoholic Steatohepatitis (NASH) Market Variables, Trends & Scope
           4.1. Market Lineage Outlook
           4.2. Penetration and Growth Prospect Mapping
           4.3. Industry Value Chain Analysis
           4.4. Cost Analysis Breakdown
           4.5. Technology Overview
           4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Global Nonalcoholic Steatohepatitis (NASH) Market Overview
           5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                             5.1.1.1. Increasing focus of Nonalcoholic Steatohepatitis (NASH) Companies on Brand Protection
                             5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                             5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                             5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Nonalcoholic Steatohepatitis (NASH) Market Analysis Tools
           6.1. Industry Analysis - Porter’s
                   6.1.1. Supplier Power
                   6.1.2. Buyer Power
                   6.1.3. Substitution Threat
                   6.1.4. Threat from New Entrants
                   6.1.5. Competitive Rivalry
           6.2. Pestel Analysis
                   6.2.1. Political Landscape
                   6.2.2. Environmental Landscape
                   6.2.3. Social Landscape
                   6.2.4. Technology Landscape
                   6.2.5. Legal Landscape
           6.3. Major Deals And Strategic Alliances Analysis
                   6.3.1. Joint Ventures
                   6.3.2. Mergers and Acquisitions
                   6.3.3. Licensing and Partnership
                   6.3.4. Technology Collaborations
                   6.3.5. Strategic Divestments
           6.4. Market Entry Strategies
           6.5. Case Studies
7. Global Nonalcoholic Steatohepatitis (NASH) Market, By Disease Cause Historical Analysis and Forecast 2020-2027 (USD Million)
           7.1. Hypertension
           7.2. Heart Disease
           7.3. High Blood Lipid
           7.4. Type 2 Diabetes
           7.5. Obesity
8. Global Nonalcoholic Steatohepatitis (NASH) Market, By Drug Type Historical Analysis and Forecast 2020-2027 (USD Million)
           8.1. Vitamin E & Pioglitazone
           8.2. Ocaliva
           8.3. Elafibranor
           8.4. Selonsertib
           8.5. Cenicriviroc
           8.6. Others
9. Global Nonalcoholic Steatohepatitis (NASH) Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
           9.1. Hospitals
           9.2. Clinics
           9.3. Homecare settings
10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           10.1. Introduction
           10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     10.2.1. U.S.A
                     10.2.2. Canada
                     10.2.3. Mexico
           10.3. Market Size (USD Million) Forecast for North America 2020-2027 
11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           11.1. Introduction
           11.2. Regional Market Trends
           11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     11.3.1. Brazil
                     11.3.2. Venezuela
                     11.3.3. Argentina
                     11.3.4. Rest of Latin America
           11.4. Market Size (USD Million) Forecast for Latin America 2020-2027  
12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           12.1. Introduction
           12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     12.2.1. Germany
                     12.2.2. U.K
                     12.2.3. France
                     12.2.4. Italy
                     12.2.5. Spain
                     12.2.6. Russia
                     12.2.7. Poland
                     12.2.8. Switzerland
                     12.2.9. Rest of Western Europe
           12.3. Market Size (USD Million) Forecast for Europe 2020-2027
13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           13.1. Introduction
           13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     13.2.1. Japan
                     13.2.2. China
                     13.2.3. Singapore
                     13.2.4. India
                     13.2.5. Australia and New Zealand
                     13.2.6. ASEAN
                     13.2.7. South Korea
                     13.2.8. Taiwan
                     13.2.9. Rest of Asia Pacific
           13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           14.1. Introduction
           14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     14.2.1. Saudi Arabia
                     14.2.2. UAE
                     14.2.3. South Africa
                     14.2.4. Egypt
           14.3. Market Size (USD Million) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
           15.1. Genfit
                     15.1.1. Company Overview
                     15.1.2. Product Portfolio
                     15.1.3. SWOT Analysis
                     15.1.4. Financial Overview
                     15.1.5. Strategic Overview
           15.2. Intercept Pharmaceuticals
                     15.2.1. Company Overview
                     15.2.2. Product Portfolio
                     15.2.3. SWOT Analysis
                     15.2.4. Financial Overview
                     15.2.5. Strategic Overview
           15.3. Gilead Sciences
                     15.3.1. Company Overview
                     15.3.2. Product Portfolio
                     15.3.3. SWOT Analysis
                     15.3.4. Financial Overview
                     15.3.5. Strategic Overview
           15.4. Tobira Therapeutics
                     15.4.1. Company Overview
                     15.4.2. Product Portfolio
                     15.4.3. SWOT Analysis
                     15.4.4. Financial Overview
                     15.4.5. Strategic Overview
           15.5 Galmed Pharmaceuticals
                     15.5.1. Company Overview
                     15.5.2. Product Portfolio
                     15.5.3. SWOT Analysis
                     15.5.4. Financial Overview
                     15.5.5. Strategic Overview
           15.6 Bristol-Myers Squibb
                     15.6.1. Company Overview
                     15.6.2. Product Portfolio
                     15.6.3. SWOT Analysis
                     15.6.4. Financial Overview
                     15.6.5. Strategic Overview
           15.7. Cirius Therapeutics
                     15.7.1. Company Overview
                     15.7.2. Product Portfolio
                     15.7.3. SWOT Analysis
                     15.7.4. Financial Overview
                     15.7.5. Strategic Overview
           15.8. Conatus Pharmaceuticals
                     15.8.1. Company Overview
                     15.8.2. Product Portfolio
                     15.8.3. SWOT Analysis
                     15.8.4. Financial Overview
                     15.8.5. Strategic Overview
           15.9. Allergan
                     15.9.1. Company Overview
                     15.9.2. Product Portfolio
                     15.9.3. SWOT Analysis
                     15.9.4. Financial Overview
                     15.9.5. Strategic Overview
           15.10. Inventiva
                     15.10.1. Company Overview
                     15.10.2. Product Portfolio
                     15.10.3. SWOT Analysis
                     15.10.4. Financial Overview
                     15.10.5. Strategic Overview
16. FutureWise SME Key Takeaway Points for Client

Tables

Figures